

*This report contains the collective views of an international group of experts and  
does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**814**

# **WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION**

Forty-first Report



**World Health Organization**

**Geneva 1991**

WHO Library Cataloguing in Publication Data

WHO Expert Committee on Biological Standardization  
WHO Expert Committee on Biological Standardization : forty-first report.

(World Health Organization technical report series ; 814)

1. Biological products — standards

I. Series

ISBN 92 4 120814 7  
ISSN 0512-3054

(NLM Classification: QW 800)

**© World Health Organization 1991**

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

**Printed in Switzerland**

91/8920 – Benteli – 6000

# Contents

|   |    |
|---|----|
| Introduction  | 1  |
| <b>General</b>  | 1  |
| Growth factors and cytokines  | 1  |
| International reference preparations derived from materials of human origin                                       | 1  |
| Distribution of international reference materials by the four International Laboratories for Biological Standards | 2  |
| WHO Bank of Vero cells for the production of biologicals  | 2  |
| Revision of the publication <i>Biological substances: international standards and reference reagents, 1986</i>    | 4  |
| Diphtheria toxoid potency assays  | 4  |
| Antivenoms – guidelines for potency assay   | 4  |
| Residual DNA in biological products from continuous cell lines  | 5  |
| Potency of oral poliomyelitis vaccine   | 5  |
| Potency of live measles vaccine   | 6  |
| Common matrix for immunoassays of thyroid-stimulating hormone   | 6  |
| <b>Antibiotics</b>  | 6  |
| Teicoplanin   | 6  |
| <b>Antibodies</b>   | 7  |
| Rabies immunoglobulin   | 7  |
| Anti-measles serum  | 7  |
| Anti-poliovirus serum   | 7  |
| Cytomegalovirus immunoglobulin  | 7  |
| Anti- <i>Haemophilus influenzae</i> type b polysaccharide serum   | 8  |
| Tetanus immunoglobulin  | 8  |
| <b>Antigens</b>   | 8  |
| International Reference Preparation of BCG Vaccine  | 8  |
| <b>Blood products and related substances</b>  | 9  |
| Anti-D (anti-Rh <sub>0</sub> ) complete blood-typing serum (chemically modified)                                  | 9  |
| Antithrombin III concentrate  | 9  |
| Thrombin  | 9  |
| Plasma fibrinogen   | 10 |
| <b>Endocrinological and related substances</b>  | 10 |
| Recombinant-DNA-derived erythropoietin  | 10 |
| Porcine inhibin   | 10 |
| Human inhibin   | 11 |
| Anti-thyroid microsome antibodies   | 11 |
| Insulin-like growth factor-1  | 11 |
| Human calcitonin  | 11 |
| Porcine calcitonin  | 11 |
| <b>Cytokines</b>  | 12 |
| Granulocyte/macrophage colony-stimulating factor  | 12 |
| Granulocyte colony-stimulating factor   | 12 |
| Tumour necrosis factor, alpha   | 12 |
| Interleukin-1 alpha and beta  | 12 |

|   |    |
|---|----|
| <b>Requirements for biological substances</b>   | 12 |
| Requirements for <i>Haemophilus</i> type b conjugate vaccines   | 12 |
| Requirements for influenza vaccine (inactivated) (revised 1990)   | 13 |
| Pharmaceutical and biological products prepared by recombinant DNA technology   | 13 |
| Requirements for antimicrobial susceptibility tests   |    |
| I. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1990)  | 13 |
| Guidelines and definitions for the drafting of Requirements for Biological Substances   | 13 |
| Guidelines on quality assurance for biologicals   | 14 |
| <br>Annex 1   |    |
| Requirements for <i>Haemophilus</i> type b conjugate vaccines   | 15 |
| <br>Annex 2   |    |
| Requirements for influenza vaccine (inactivated) (revised 1990)   | 38 |
| <br>Annex 3   |    |
| Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology                  | 59 |
| <br>Annex 4   |    |
| Requirements for antimicrobial susceptibility tests: I. Agar diffusion tests using antimicrobial susceptibility discs (addendum 1990) | 71 |
| <br>Annex 5   |    |
| Biological substances: international standards and reference reagents   | 72 |
| <br>Annex 6   |    |
| Requirements for biological substances and other sets of recommendations  | 74 |
| <br>Note  |    |
| Amendment to the list of laboratories approved by WHO for the production of yellow fever vaccine                                      | 79 |

# WHO Expert Committee on Biological Standardization

Geneva, 16–23 October 1990

## Members

- Dr Darodjatun, Director, “Bio Farma”, Bandung, Indonesia
- Professor E. M. Essien, Director, National Institute for Medical Research, Yaba, Lagos, Nigeria
- Dr C. Guthrie, Operations Director, Commonwealth Serum Laboratories, Parkville, Victoria, Australia (*Vice-Chairman*)
- Dr A. Homma, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
- Dr Z. Khan, Principal Scientific Officer, Quality Control Division, National Institute of Health, Islamabad, Pakistan
- Mr J. Lyng, State Serum Institute, Copenhagen, Denmark (*Chairman*)
- Professor N. V. Medunitsin, Director, Tarasevič State Institute for the Standardization and Control of Medical Biological Preparations, Moscow, USSR
- Dr J. C. Petricciani, Vice-President for Medical and Regulatory Affairs, Pharmaceutical Manufacturers Associations, Washington, DC, USA (*Rapporteur*)
- Professor W. G. van Aken, Medical Director, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands
- Mr Zhou Hai-jun, Director, National Institute for the Control of Pharmaceutical and Biological Products, Temple of Heaven, Beijing, China

## Representatives of other organizations

- Council of Europe*
- Mr P. Castle, European Pharmacopoeia, Strasbourg, France
- Mr J.-M. Spieser, European Pharmacopoeia, Strasbourg, France

## Secretariat

- Dr T. W. Barrowcliffe, Department of Blood Products, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr V. Grachev, Scientist, Biologicals, WHO, Geneva, Switzerland
- Dr S. Jeffcoate, Department of Endocrinology, National Institute for Biological Standards and Control, Potters Bar, Herts., England (*Temporary Adviser*)
- Dr D. Magrath, Chief, Biologicals, WHO, Geneva, Switzerland (*Secretary*)
- Dr J. Milstien, Scientist, Biologicals, WHO, Geneva, Switzerland
- Dr H. Mirchamsy, Associate Director, Razi State Institute of Sera and Vaccines, Teheran, Islamic Republic of Iran (*Temporary Adviser*)
- Dr R. Netter, General Inspectorate of Social Affairs, Ministry of Solidarity, Health, and Social Protection, Paris, France (*Temporary Adviser*)
- Dr H. Sing, Director, Central Research Institute, Kasauli, India (*Temporary Adviser*)
- Dr P. Sizaret, Scientist, Biologicals, WHO, Geneva, Switzerland
- Dr W. W. Wright, Senior Scientist, Drug Standards Division, United States Pharmacopoeia, Rockville, MD, USA (*Temporary Adviser*)



## Introduction

The WHO Expert Committee on Biological Standardization met in Geneva from 16 October to 23 October 1990. The meeting was opened on behalf of the Director-General by Dr J. Idänpään-Heikkilä, Deputy Director, Division of Drug Management and Policies.

## General

### Growth factors and cytokines

At its thirty-ninth meeting (WHO Technical Report Series, No. 786, 1989, p.12) the Committee discussed recombinant cytokines. More recently, polypeptide growth factors have assumed increasing importance. Taking this into account, the Committee discussed issues associated with the classification and standardization of various recombinant-DNA-derived products, including growth factors, cytokines and other biological response modifiers. It requested the WHO Secretariat to review the situation and evaluate how WHO should interact with other groups interested in the same issues.

The term “polypeptide growth factors” refers to polypeptides (of relative molecular mass up to 80 000) having a regulatory action on cell differentiation or proliferation through interaction with specific high-affinity cell-surface receptors, and active only at short range (as opposed to classic hormones which act on specific distant targets). Research in this field is expanding rapidly with the discovery both of new growth factors and of new effects of those already known; at the same time, there is increasing evidence of the complexity of the interactions between different growth factors.

The therapeutic and diagnostic potential of a number of growth factors is being investigated, and the need for international reference materials is becoming evident. The major potential therapeutic applications of such growth factors are as anticancer, anti-inflammatory, immunomodulatory and wound-healing agents, and these are currently being investigated. Priority is being given to: (i) *epidermal growth factor* (EGF), currently undergoing clinical trials as a wound-healing agent and being evaluated in cancer chemotherapy; (ii) *acidic and basic fibroblast growth factors* (aFGF, bFGF), a group of polypeptides with potential as wound-healing agents; and (iii) *platelet-derived growth factor* (PDGF) for use in wound-healing and the treatment of chronic ulcers (e.g., varicose, diabetic).

### International reference preparations derived from materials of human origin

The Committee noted that the Guidelines for the Preparation, Characterization and Establishment of International and Other Standards

and Reference Reagents for Biological Substances, revised in 1989 (WHO Technical Report Series, No. 800, p. 181), required that, for safety reasons, biological materials of human origin being considered for the preparation of international reference materials should be tested to ensure the absence of infectivity markers for hepatitis B virus human immunodeficiency virus (HIV) and other pathogens.

In considering the establishment of new or replacement international reference materials derived from materials of human origin, and in reviewing the present status of candidate materials that may later be proposed for establishment, the Committee emphasized the need for the starting materials to be screened for hepatitis C virus antibody as well, since tests licensed for that purpose were now available.

#### **Distribution of international reference materials by the four International Laboratories for Biological Standards**

The Committee noted that the distribution of international reference materials by the four International Laboratories for Biological Standards had continued in 1989 (Table 1) (BS/90.1644).<sup>1</sup> It also noted that the proportions of recipient laboratories in different categories (national control authorities, manufacturers, research laboratories and universities) had been tabulated (Table 2). In view of the widespread use of, and increasing need for, international reference materials, particularly for the products of biotechnology, the Committee stressed the importance of the distribution of such materials in promoting the international standardization of biological products, thus facilitating their free circulation between countries, to the benefit of the health of the peoples of the world.

The Committee agreed that, in order to assign priorities, it would be useful to gather information, through a questionnaire circulated to recipients, on the ways in which the international reference materials are used. The Committee therefore requested the WHO Secretariat to obtain such information and to identify trends in the distribution and use of these materials.

#### **WHO bank of Vero cells for the production of biologicals**

The Committee was informed of progress in the distribution of ampoules from the WHO bank of Vero cells referred to in its fortieth report (WHO Technical Report Series, No. 800, 1990, p. 11), and noted that, since the cell bank was established in 1989, 26 requests for such ampoules had been received. The Committee was also informed that the WHO Secretariat planned to establish a WHO bank of BHK-21 cells.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_30753](https://www.yunbaogao.cn/report/index/report?reportId=5_30753)

